Opinion|Videos|January 27, 2025
Real-World (RW) Observations from CAR T in R/R Myeloma
Author(s)Amrita Krishnan, MD
The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but with some differences from clinical trials. Ide-cel demonstrates effectiveness in patients with prior BCMA exposure, though responses may be impacted. Compared with standard of care (SOC), both ide-cel and cilta-cel show superior outcomes in terms of response rates and progression-free survival, though long-term data are still emerging in real-world settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on real-world (RW) evidence surrounding the use of CAR T for R/R MM.
- RW ide-cel and prior BCMA exposure
- SOC comparison, ide-cel and cilta-cel
Advertisement
Related to this article
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.
In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
2
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
3
T-DXd Significantly Improves PFS in First-Line HER2-Mutant NSCLC
4
Amivantamab-Chemotherapy Shows Longest OS Reported in EGFR Exon 20 NSCLC
5